ICIs are monoclonal antibodies targeting the programmed cell death protein 1 (PD1), the programmed death ligand 1 (PDL1), and/or the cytotoxic T lymphocyte-associated protein 4 (CTLA-4), enhancing the immune system response against tumor cells [4,5,6]. This evidence concerns the gene CTLA4 and neoplasm.